Pharmabiz

Bristol announces positive results from phase 3 CheckMate -648 trial of Opdivo plus chemotherapy & Opdivo plus Yervoy to treat unresectable advanced or metastatic ESCC

Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...
Seeking Alpha

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable ...

In Checkmate 648, serious adverse reactions occurred in 62% of patients receiving OPDIVO in combination with chemotherapy (n=310). The most frequent serious adverse reactions reported in ≥2% of ...
Pharmabiz

BMS announces positive results from phase 3 CheckMate -9LA trial of Opdivo plus Yervoy with two cycles of chemotherapy for patients with metastatic NSCLC

Bristol Myers Squibb (BMS) announced four-year follow-up results from the phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy ...
ascopubs.org

Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive ...

This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.